BridgeBio presents long-term acoramidis data showing sustained sTTR gains, stable KCCQ scores

Reuters03-30

BridgeBio presents long-term acoramidis data showing sustained sTTR gains, stable KCCQ scores

BridgeBio published long-term open-label extension results for acoramidis in transthyretin amyloid cardiomyopathy, tracking serum transthyretin levels and Kansas City Cardiomyopathy Questionnaire Overall Summary scores through month 54.
Continuous acoramidis use maintained higher serum transthyretin, with mean change from baseline of 8 mg/dL at month 54.
Patients switched from placebo to acoramidis showed rapid serum transthyretin increase by month 31, with mean change from baseline of 7.4 mg/dL.
Health-status scores were reported as stabilized through month 54, with mean change from baseline of -4.8 points for continuous treatment.
Placebo-to-acoramidis group showed mean change from baseline of -12.5 points in KCCQ-OS at month 54.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BridgeBio Pharma Inc. published the original content used to generate this news brief on March 30, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2623444983?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-30 23:34","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2623444983","market":"nz","top_or_hot":-1,"title":"BridgeBio presents long-term acoramidis data showing sustained sTTR gains, stable KCCQ scores","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      BridgeBio presents long-term acoramidis data showing sustained sTTR gains, stable KCCQ scores\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          BridgeBio published long-term open-label extension results for acoramidis in transthyretin amyloid cardiomyopathy, tracking serum transthyretin levels and Kansas City Cardiomyopathy Questionnaire Overall Summary scores through month 54.\n        </li>\n<li>\n          Continuous acoramidis use maintained higher serum transthyretin, with mean change from baseline of 8 mg/dL at month 54.\n        </li>\n<li>\n          Patients switched from placebo to acoramidis showed rapid serum transthyretin increase by month 31, with mean change from baseline of 7.4 mg/dL.\n        </li>\n<li>\n          Health-status scores were reported as stabilized through month 54, with mean change from baseline of -4.8 points for continuous treatment.\n        </li>\n<li>\n          Placebo-to-acoramidis group showed mean change from baseline of -12.5 points in KCCQ-OS at month 54.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/BBIO\">BridgeBio Pharma</a> Inc. published the original content used to generate this news brief on March 30, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BridgeBio presents long-term acoramidis data showing sustained sTTR gains, stable KCCQ scores</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBridgeBio presents long-term acoramidis data showing sustained sTTR gains, stable KCCQ scores\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-30 23:34</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      BridgeBio presents long-term acoramidis data showing sustained sTTR gains, stable KCCQ scores\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          BridgeBio published long-term open-label extension results for acoramidis in transthyretin amyloid cardiomyopathy, tracking serum transthyretin levels and Kansas City Cardiomyopathy Questionnaire Overall Summary scores through month 54.\n        </li>\n<li>\n          Continuous acoramidis use maintained higher serum transthyretin, with mean change from baseline of 8 mg/dL at month 54.\n        </li>\n<li>\n          Patients switched from placebo to acoramidis showed rapid serum transthyretin increase by month 31, with mean change from baseline of 7.4 mg/dL.\n        </li>\n<li>\n          Health-status scores were reported as stabilized through month 54, with mean change from baseline of -4.8 points for continuous treatment.\n        </li>\n<li>\n          Placebo-to-acoramidis group showed mean change from baseline of -12.5 points in KCCQ-OS at month 54.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/BBIO\">BridgeBio Pharma</a> Inc. published the original content used to generate this news brief on March 30, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4588","symbol_name":"碎股","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260330:nNDLb5xPyT:1","article_id":"2623444983","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2623444983","pubTimestamp":1774884886,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BridgeBio published long-term open-label extension results for acoramidis in transthyretin amyloid cardiomyopathy, tracking serum transthyretin levels and Kansas City Cardiomyopathy Questionnaire Overall Summary scores through month 54.Continuous acoramidis use maintained higher serum transthyretin, with mean change from baseline of 8 mg/dL at month 54.Patients switched from placebo to acoramidis showed rapid serum transthyretin increase by month 31, with mean change from baseline of 7.4 mg/dL.Health-status scores were reported as stabilized through month 54, with mean change from baseline of -4.8 points for continuous treatment.Placebo-to-acoramidis group showed mean change from baseline of -12.5 points in KCCQ-OS at month 54.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4588":"碎股","BK4585":"ETF&股票定投概念","BK4505":"高瓴资本持仓","BK4139":"生物科技","BBIO":"BridgeBio Pharma, Inc."},"translate_title":"BridgeBio提供acoramidis长期数据，显示sTTR持续增加，KCCQ评分稳定","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BBIO":0.9},"content_text":"BridgeBio presents long-term acoramidis data showing sustained sTTR gains, stable KCCQ scores\n    \n\n\n          BridgeBio published long-term open-label extension results for acoramidis in transthyretin amyloid cardiomyopathy, tracking serum transthyretin levels and Kansas City Cardiomyopathy Questionnaire Overall Summary scores through month 54.\n        \n\n          Continuous acoramidis use maintained higher serum transthyretin, with mean change from baseline of 8 mg/dL at month 54.\n        \n\n          Patients switched from placebo to acoramidis showed rapid serum transthyretin increase by month 31, with mean change from baseline of 7.4 mg/dL.\n        \n\n          Health-status scores were reported as stabilized through month 54, with mean change from baseline of -4.8 points for continuous treatment.\n        \n\n          Placebo-to-acoramidis group showed mean change from baseline of -12.5 points in KCCQ-OS at month 54.\n        \n\n\n\n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BridgeBio Pharma Inc. published the original content used to generate this news brief on March 30, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2623444983","isCrawlerRequest":true}